|
|||||
|
|
Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation |
|
| Authors: | Glenn S. Van Aller Nicolas Reynoird Olena Barbash Michael Huddleston Shichong Liu Anne-Flore Zmoos Patrick McDevitt Robert Sinnamon BaoChau Le Gloria Mas Roland Annan Julien Sage Benjamin A. Garcia Peter J. Tummino Or Gozani Ryan G. Kruger |
| Affiliation: | 1.GlaxoSmithKline; Collegeville, PA USA;2.Department of Biolog; Stanford University; Stanford, CA USA;3.Department of Molecular Biology; Princeton University; Princeton NJ USA;4.Department of Pediatrics; Stanford School of Medicine; Stanford, CA USA;5.Department of Biology; Stanford University; Stanford, CA USA |
| Abstract: | Smyd3 is a lysine methyltransferase implicated in chromatin and cancer regulation. Here we show that Smyd3 catalyzes histone H4 methylation at lysine 5 (H4K5me). This novel histone methylation mark is detected in diverse cell types and its formation is attenuated by depletion of Smyd3 protein. Further, Smyd3-driven cancer cell phenotypes require its enzymatic activity. Thus, Smyd3, via H4K5 methylation, provides a potential new link between chromatin dynamics and neoplastic disease. |
| Keywords: | cancer epigenetics lysine methylation oncogene oncology Smyd3 |